BRPI0307267B8 - uso de compostos inibidores de beta-lactamases e composições farmacêuticas para terapia antibacteriana - Google Patents

uso de compostos inibidores de beta-lactamases e composições farmacêuticas para terapia antibacteriana

Info

Publication number
BRPI0307267B8
BRPI0307267B8 BRPI0307267A BR0307267A BRPI0307267B8 BR PI0307267 B8 BRPI0307267 B8 BR PI0307267B8 BR PI0307267 A BRPI0307267 A BR PI0307267A BR 0307267 A BR0307267 A BR 0307267A BR PI0307267 B8 BRPI0307267 B8 BR PI0307267B8
Authority
BR
Brazil
Prior art keywords
beta
pharmaceutical compositions
inhibitor compounds
lactamase inhibitor
antibacterial therapy
Prior art date
Application number
BRPI0307267A
Other languages
English (en)
Portuguese (pt)
Other versions
BRPI0307267B1 (pt
BR0307267A (pt
Inventor
Fromentin Claude
Alan Rowlands David
Aszodi Jozsef
Lampilas Maxime
Original Assignee
Astra Zeneca Holding France
Aventis Pharma Sa
Novexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0307267(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Zeneca Holding France, Aventis Pharma Sa, Novexel filed Critical Astra Zeneca Holding France
Publication of BR0307267A publication Critical patent/BR0307267A/pt
Publication of BRPI0307267B1 publication Critical patent/BRPI0307267B1/pt
Publication of BRPI0307267B8 publication Critical patent/BRPI0307267B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0307267A 2002-01-28 2003-01-27 uso de compostos inibidores de beta-lactamases e composições farmacêuticas para terapia antibacteriana BRPI0307267B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
PCT/FR2003/000243 WO2003063864A2 (fr) 2002-01-28 2003-01-27 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (3)

Publication Number Publication Date
BR0307267A BR0307267A (pt) 2004-12-07
BRPI0307267B1 BRPI0307267B1 (pt) 2016-02-10
BRPI0307267B8 true BRPI0307267B8 (pt) 2021-05-25

Family

ID=27619669

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0307267A BRPI0307267B8 (pt) 2002-01-28 2003-01-27 uso de compostos inibidores de beta-lactamases e composições farmacêuticas para terapia antibacteriana

Country Status (44)

Country Link
US (4) US7612087B2 (enExample)
EP (2) EP1480644B1 (enExample)
JP (1) JP4472346B2 (enExample)
KR (1) KR100979079B1 (enExample)
CN (3) CN101406471A (enExample)
AR (2) AR038234A1 (enExample)
AT (1) ATE484281T1 (enExample)
AU (1) AU2003214335B2 (enExample)
BE (1) BE2016C069I2 (enExample)
BR (1) BRPI0307267B8 (enExample)
CA (1) CA2474043C (enExample)
CL (1) CL2011000009A1 (enExample)
CO (1) CO5601014A2 (enExample)
CR (2) CR7387A (enExample)
CY (3) CY1111061T1 (enExample)
DE (1) DE60334527D1 (enExample)
DK (2) DK1480644T3 (enExample)
EA (1) EA007220B1 (enExample)
EC (1) ECSP045193A (enExample)
ES (2) ES2401855T3 (enExample)
FR (2) FR2835186B1 (enExample)
HR (1) HRP20040686B1 (enExample)
HU (1) HUS1600055I1 (enExample)
IL (1) IL163167A (enExample)
JO (1) JO2646B1 (enExample)
LT (1) LTC1480644I2 (enExample)
MA (1) MA26351A1 (enExample)
MX (1) MXPA04006621A (enExample)
MY (1) MY140638A (enExample)
NL (1) NL300847I2 (enExample)
NO (3) NO335195B1 (enExample)
NZ (1) NZ533936A (enExample)
OA (1) OA12761A (enExample)
PE (1) PE20030969A1 (enExample)
PL (1) PL220725B1 (enExample)
PT (2) PT1480644E (enExample)
RS (1) RS52137B (enExample)
SI (2) SI1480644T1 (enExample)
TN (1) TNSN04137A1 (enExample)
TW (1) TWI293071B (enExample)
UA (1) UA80271C2 (enExample)
UY (1) UY27626A1 (enExample)
WO (1) WO2003063864A2 (enExample)
ZA (1) ZA200405607B (enExample)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
DK2484680T3 (da) * 2005-12-07 2013-09-08 Basilea Pharmaceutica Ag Nyttige kombinationer af monolactam-antibiotika med beta-lactamase-inhibitorer
EP2040698A4 (en) * 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
MX2009004290A (es) * 2006-10-23 2009-07-27 Irm Llc Inhibidores de proteasas de catepsina.
WO2008150470A1 (en) * 2007-05-31 2008-12-11 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
RS53862B1 (sr) * 2008-01-18 2015-08-31 Merck Sharp & Dohme Corp. Inhibitori beta-laktamaze
US20110046101A1 (en) * 2008-03-17 2011-02-24 Dmitrienko Gary I Bate-lactamase inhibitors
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
JP5501983B2 (ja) * 2008-06-11 2014-05-28 塩野義製薬株式会社 オキシカルバモイル化合物およびその使用
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
PL3412676T3 (pl) 2010-08-10 2021-04-06 Melinta Therapeutics, Inc. Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne
KR101836554B1 (ko) * 2010-12-22 2018-04-19 메이지 세이카 파루마 가부시키가이샤 광학 활성인 디아자비시클로옥탄 유도체 및 그의 제조법
US8772490B2 (en) * 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
US8822450B2 (en) * 2011-08-27 2014-09-02 Wockhardt Ltd. 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
CN103781787B (zh) * 2011-09-13 2015-09-23 沃克哈特有限公司 含氮化合物及其用途
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
KR20150003777A (ko) 2012-03-30 2015-01-09 큐비스트 파마슈티컬즈 인코포레이티드 이속사졸 β-락타마제 억제제
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
CN104334558A (zh) 2012-03-30 2015-02-04 丘比斯特药物股份有限公司 1,3,4-噁二唑和1,3,4-噻二唑β-内酰胺酶抑制剂
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX366948B (es) 2012-05-30 2019-07-30 Meiji Seika Pharma Co Ltd Nuevo inhibidor de beta-lactamasa y proceso para prepararlo.
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP2961751B1 (en) * 2012-08-25 2018-03-21 Wockhardt Limited 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9132140B2 (en) 2013-01-04 2015-09-15 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2015008628A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
EP2970338A1 (en) 2013-03-14 2016-01-20 Merck Sharp & Dohme Corp. Crystalline form of a beta-lactamase inhibitor
ES2793201T3 (es) 2013-09-24 2020-11-13 Meiji Seika Pharma Co Ltd Procedimiento de producción de derivados y productos intermedios de diazabiciclooctano
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
EP3613740A1 (en) 2013-10-08 2020-02-26 Meiji Seika Pharma Co., Ltd. Preparation of a diazabicyclooctane derivative
JP2017506240A (ja) * 2014-02-20 2017-03-02 ウォックハート リミテッド 抗菌剤を含む医薬組成物
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
EP3140310B1 (en) 2014-05-05 2019-08-07 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
ES2985626T3 (es) 2014-05-05 2024-11-06 Melinta Therapeutics Inc Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
CA2947041A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
US10206937B2 (en) 2014-07-01 2019-02-19 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
TR201905233T4 (tr) 2014-11-17 2019-05-21 Entasis Therapeutics Ltd Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi.
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
TWI691499B (zh) 2014-12-05 2020-04-21 日商明治製菓藥業股份有限公司 二氮雜雙環辛烷衍生物之結晶及安定的凍結乾燥製劑的製造法
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2017014080A (es) * 2015-05-07 2018-07-06 Mutabilis Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
US10167283B2 (en) 2015-09-16 2019-01-01 Suanzhu Pharma Co., Ltd. β-lactamase inhibitors and uses thereof
US9951072B2 (en) 2015-10-02 2018-04-24 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
WO2018053215A1 (en) 2016-09-16 2018-03-22 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
RU2019124705A (ru) 2017-02-06 2021-02-05 Мутабилис Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций
SG11201909443YA (en) 2017-05-08 2019-11-28 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
KR102626967B1 (ko) 2017-10-11 2024-01-18 큐펙스 바이오파마 인코포레이티드 보론산 유도체 및 이의 합성
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
HUE063324T2 (hu) 2018-08-09 2024-01-28 Antabio Sas Diaza-biciklo-oktanonok mint a szerin-béta-laktamázok inhibitorai
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
CN115151544B (zh) * 2020-09-01 2024-08-16 宁夏农林科学院 β-内酰胺酶抑制剂及其制备
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
US12410166B2 (en) 2021-05-07 2025-09-09 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
KR20240041506A (ko) 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN116375706B (zh) * 2023-02-22 2025-02-14 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
AU626427B2 (en) 1989-06-09 1992-07-30 Pharmacia & Upjohn Company Heterocyclic amines having central nervous system activity
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
CA2173116C (en) 1993-09-29 2006-02-28 Barry Burns Ring-expanded nucleosides and nucleotides
CN1046515C (zh) * 1993-12-29 1999-11-17 辉瑞大药厂 二氮杂双环神经激肽拮抗剂
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
AU715229B2 (en) * 1996-01-03 2000-01-20 Smithkline Beecham Plc Carbamoyloxy derivatives of mutiline and their use as antibacterials
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
US6329389B1 (en) 1998-04-08 2001-12-11 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
AU4698399A (en) 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
CZ20011900A3 (cs) 1998-12-18 2002-02-13 Schering Corporation Látka, způsob léčby a farmaceutický přípravek tuto látku obsahující a jeho pouľití k inhibici farnesyl protein transferázy
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
AU7556800A (en) 1999-10-07 2001-05-10 Tadeka Chemical Industries, Ltd. Amine derivatives
WO2001079206A1 (en) 2000-04-18 2001-10-25 Sumitomo Pharmaceuticals Company, Limited Tricyclic quinazolinediones
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
EP1408970B1 (en) 2001-02-22 2007-05-09 School Of Pharmacy, University Of London Indolines and tetrahydro-quinolines as prodrugs for tumour treatment
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
NL300847I2 (enExample) 2017-01-03
HK1077205A1 (zh) 2006-02-10
WO2003063864A2 (fr) 2003-08-07
CY1111061T1 (el) 2015-06-11
CN100563653C (zh) 2009-12-02
UA80271C2 (uk) 2007-09-10
CA2474043C (fr) 2011-08-02
CN101406471A (zh) 2009-04-15
EP2279737A1 (fr) 2011-02-02
OA12761A (fr) 2006-07-04
BE2016C069I2 (enExample) 2022-05-17
CN1994301A (zh) 2007-07-11
ZA200405607B (en) 2005-09-28
DK1480644T3 (da) 2011-01-24
PT1480644E (pt) 2011-01-17
EP2279737B1 (fr) 2012-10-31
BRPI0307267B1 (pt) 2016-02-10
HUS1600055I1 (hu) 2017-01-30
ATE484281T1 (de) 2010-10-15
CY2016042I1 (el) 2017-03-15
MA26351A1 (fr) 2004-10-01
AR038234A1 (es) 2005-01-05
HRP20040686B1 (hr) 2013-02-28
US20090215747A1 (en) 2009-08-27
TWI293071B (en) 2008-02-01
TNSN04137A1 (fr) 2007-03-12
NO2016024I2 (no) 2016-12-15
CR20120356A (es) 2012-10-05
EP1480644A2 (fr) 2004-12-01
JP2005523897A (ja) 2005-08-11
ES2356813T3 (es) 2011-04-13
PL220725B1 (pl) 2015-12-31
AR100790A2 (es) 2016-11-02
NO2025027I1 (no) 2025-06-13
NZ533936A (en) 2007-05-31
FR16C1019I1 (fr) 2017-02-03
CY2016042I2 (el) 2017-03-15
FR16C1019I2 (fr) 2017-12-29
MY140638A (en) 2010-01-15
CY1114417T1 (el) 2016-08-31
CN100482225C (zh) 2009-04-29
MXPA04006621A (es) 2004-10-04
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
EA007220B1 (ru) 2006-08-25
WO2003063864A3 (fr) 2004-03-11
RS52137B (sr) 2012-08-31
PL371601A1 (pl) 2005-06-27
KR100979079B1 (ko) 2010-08-31
ECSP045193A (es) 2004-08-27
YU65804A (sh) 2006-08-17
JO2646B1 (en) 2012-06-17
EA200400981A1 (ru) 2005-02-24
NO335195B1 (no) 2014-10-20
HRP20040686A2 (en) 2004-12-31
DK2279737T3 (da) 2013-02-11
CO5601014A2 (es) 2006-01-31
HK1105864A1 (zh) 2008-02-29
US7612087B2 (en) 2009-11-03
CL2011000009A1 (es) 2011-03-25
KR20040081473A (ko) 2004-09-21
FR2835186B1 (fr) 2006-10-20
CN1655781A (zh) 2005-08-17
LTC1480644I2 (lt) 2018-09-10
UY27626A1 (es) 2003-08-29
EP1480644B1 (fr) 2010-10-13
AU2003214335B2 (en) 2007-04-05
ES2401855T3 (es) 2013-04-25
DE60334527D1 (de) 2010-11-25
US20050020572A1 (en) 2005-01-27
US20110245254A1 (en) 2011-10-06
SI1480644T1 (sl) 2011-03-31
CR7387A (es) 2010-10-25
NO20043587L (no) 2004-08-27
US20100048528A1 (en) 2010-02-25
SI2279737T1 (sl) 2013-07-31
FR2835186A1 (fr) 2003-08-01
JP4472346B2 (ja) 2010-06-02
CA2474043A1 (fr) 2003-08-07
NO2016024I1 (no) 2016-12-15
PT2279737E (pt) 2013-02-01
IL163167A (en) 2010-04-15
LTPA2016037I1 (lt) 2017-01-10
BR0307267A (pt) 2004-12-07

Similar Documents

Publication Publication Date Title
BRPI0307267B8 (pt) uso de compostos inibidores de beta-lactamases e composições farmacêuticas para terapia antibacteriana
MX2007010072A (es) Derivados de piperidina antibacterianos.
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
BRPI0417458A (pt) compostos inibidores de dpp-iv, sais faramaceuticamente aceitáveis e pró-fármacos do mesmo, seus processos de preparação, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos na fabricação de medicamento
MX2009005603A (es) Compuestos de urea policiclicos antibacterianos.
CO6270331A2 (es) Derivados de 1,2,3-triazol para uso como inhibidores de estearoil -coenzima a desaturada
PA8591701A1 (es) Derivados de pirrolopirimidina
NO20061657L (no) Pyrolderivater med antibakteriell aktivitet
BRPI0408437A (pt) derivados de p-diaminobenzeno substituìdos, composição farmacêutica, e, uso da mesma
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
BRPI0417193B8 (pt) antibióticos híbridos de oxazolidinona-quinolona, seus sais monossódicos, dissódicos ou trissódicos e seus pró-fármacos, composições farmacêuticas, e seu uso
AU2001240578A1 (en) Pharmaceutically active aromatic guanylhydrazones
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0410050A (pt) método de tratamento ou de profilaxia de distúrbios psicóticos, distúrbios de prejuìzo intelectual ou doenças ou condições nos quais a modulação do receptor alfa7-nicotìnico é benéfica, composição farmacêutica, método de tratamento ou de profilaxia de doenças, uso de um composto, composto, e, método de preparação de um composto
TW200806321A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
TW200504030A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0002476D0 (sv) New compounds
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR0318659A (pt) derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores
BR0315106A (pt) Derivados antimicrobianos de [3.1.0]oxazolidinona bicìclica
SE0102057D0 (sv) New Salts I
SE0102058D0 (sv) New Salts II
BRPI0407456A (pt) Derivados antiproliferativos de 2-(sulfo-fenil)-aminotiazole e composições farmacêuticas, e métodos para o seu uso
BR122015020406B8 (pt) uso de compostos de formula i como inibidores de beta-lactamases e composições farmaceuticas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NOVEXEL (FR)

Free format text: TRANSFERIDO DE: AVENTIS PHARMA S.A.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: ASTRA ZENECA HOLDING FRANCE (FR)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/02/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved
B25A Requested transfer of rights approved
B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.005929/2022-10 ORIGEM: 7A VARA FEDERAL CIVEL DA SJDF PROCESSO NO: 1089546-34.2021.4.01.3400 ACAO PELO PROCEDIMENTO COMUM AUTOR: PFIZER IRELAND PHARMACEUTICALS REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI